We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.68 | -1.03% | 65.26 | 65.26 | 65.27 | 65.60 | 64.89 | 65.62 | 2,150,475 | 17:52:55 |
From Oct 2023 to Apr 2024
By Denny Jacob
Gilead Sciences posted better-than-expected top- and bottom-line results in the latest quarter, which the company credited to its virology and oncology segments.
The biopharmaceutical company logged net income of $2.18 billion, or $1.73 a share, for the third quarter ended Sept. 30, compared to $1.79 billion, or $1.42 a share, a year earlier. Adjusted earnings were $2.29 a share, above analysts' estimates of $1.92 a share.
Revenue edged up slightly to $7.05 billion from $7.04 billion a year earlier. Analysts polled by FactSet expected $6.81 billion.
Gilead said revenue was flat as increased sales in oncology and HIV were offset by lower Veklury and chronic hepatitis C virus product sales.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 07, 2023 16:36 ET (21:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
